Johnson & Johnson upgrade from Leerink, shares in S&P 500 focus
Published on 06/23/2026 at 07:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 07:11.
Johnson & Johnson (US4781601046) draws renewed analyst attention after an upgrade from Leerink Partners. The Wall Street firm now rates the S&P 500 healthcare heavyweight Outperform with a 265 dollar price target, adding a fresh impulse for the NYSE-listed shares.
What Leerink Partners changed
Leerink Partners analyst David Risinger upgraded Johnson & Johnson from Market Perform to Outperform, setting a 265 dollar price target according to a recent market summary of analyst actions. TrendSpider compiles the Leerink rating and target. The move puts Leerink in the bullish camp on the NYSE-listed blue chip.
The new 265 dollar target implies moderate upside from a spot level around 231 dollars per share, based on late Monday trading data. The upgrade comes against a backdrop of robust year-to-date performance, with Johnson & Johnson stock up double digits in 2026 in some analyst roundups, underpinned by steady demand in pharmaceuticals and MedTech.
How consensus on J&J looks now
Across the broader analyst community, Johnson & Johnson continues to attract a mix of Buy and Hold ratings from major houses that follow S&P 500 healthcare names. Aggregated data on one large broker platform show a clear majority of recommendations in the positive or neutral range, with only a small minority on the Sell side for JNJ. Fidelity’s factsheet underlines the defensive income profile.
The company’s long dividend track record remains a central point for income-focused investors. Johnson & Johnson is frequently cited in dividend research as a so-called Dividend Aristocrat, with more than six decades of consecutive annual dividend increases, a feature that often supports positive ratings in low-yield phases of the US Treasury market.
All news and analysis on the Johnson & Johnson shares
Price data, ad-hoc releases and further analyst commentary on Johnson & Johnson are bundled in the dedicated topic area.
The products behind the stock
Johnson & Johnson generates revenue primarily through prescription medicines, MedTech devices and over-the-counter consumer health products. A well-known consumer brand from the historic portfolio is Tylenol, a pain reliever that has been sold in North America for decades alongside other everyday healthcare products.
Where the J&J shares trade today
The Johnson & Johnson shares (US4781601046) traded on the NYSE at 231.33 US dollars as of 2026-06-23, 00:59 EDT, according to a large broker quote service.
Key data on the Johnson & Johnson shares
- Company: Johnson & Johnson
- ISIN: US4781601046
- WKN: 853260
- Ticker: JNJ
- Trading venue: NYSE
- Price (as of 2026-06-23, 00:59): 231.33 USD
- Market cap: 445 billion USD (as of 2026-06-23)
- Sector / industry: Health Care / Pharmaceuticals & MedTech
- Index membership: S&P 500, Dow Jones Industrial Average
- Next earnings date: 2026-07-15
This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
